The Hereditary Angioedema Therapeutics Market is developing across North America, Europe, Asia-Pacific, and other emerging regions. North America currently holds the largest share, accounting for more than 59% of the market in 2024 according to Market Research Future. Asia-Pacific is identified as the fastest-growing regional market.

North America's strong position is supported by advanced healthcare infrastructure, greater awareness of rare genetic diseases, established specialist networks, and access to innovative therapies. Europe also represents an important market because of improvements in rare-disease diagnosis, treatment availability, and healthcare systems.

Asia-Pacific provides significant future opportunities. Increasing healthcare expenditure, improving diagnostic capabilities, and growing awareness of hereditary angioedema can support wider access to treatment. Expansion of specialist healthcare infrastructure across countries such as China, Japan, India, and South Korea may further contribute to regional growth.

The competitive landscape includes major pharmaceutical and biotechnology companies such as Takeda Pharmaceutical Company Limited, CSL Behring, Shire, BioCryst Pharmaceuticals, Sobi, Pharming Group, KalVista Pharmaceuticals, and Acrotech Biopharma.

Competition is increasingly centered on targeted therapies, treatment effectiveness, patient convenience, and innovation. Companies are exploring improved formulations, oral therapies, long-acting options, and advanced biological approaches.

Strategic partnerships, regulatory approvals, clinical development, and expansion into emerging markets are expected to remain important competitive strategies as pharmaceutical companies seek to strengthen their positions in the growing HAE therapeutics market.